Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Apr 02, 2023 10:49am
149 Views
Post# 35374500

RE:RE:Paladin Labs' Revenue Guidance (2007-2012)

RE:RE:Paladin Labs' Revenue Guidance (2007-2012)GUD knows what they purchased - they know the GM concerns and they know the work they need to do on the financial side.  Nothing drastic is happening overnight.  It's a process.  It's a very good team at work so I'm not losing sleep.  None of this is new to the key players here.

Watching the EBITDA growth and the cash flow is key to operations as many other things are affecting the numbers - currencies/amortizations/etc.  That too isn't going away overnight.

Aside from that - we'll ride the losses and avoid taxes as best we can.

The only thing you and I need to decide is ... are we in or out ... and if we're in, when are we buying.

Forget about making a few bucks here and there on ups and downs.

This is an accumulation play for the longterm - OR - you likely just don't play it.  It is too slow and too boring for most investors.  It is going to be like that, with spurts of excitement.
<< Previous
Bullboard Posts
Next >>